A Randomized Dose Ranging Study of Hexadecasaccharide Including Active Control, in Patients With Unstable Angina or Non-ST-Segment Elevation Myocardial Infarction Scheduled to Undergo Percutaneous Coronary Intervention (SHINE).

Trial Profile

A Randomized Dose Ranging Study of Hexadecasaccharide Including Active Control, in Patients With Unstable Angina or Non-ST-Segment Elevation Myocardial Infarction Scheduled to Undergo Percutaneous Coronary Intervention (SHINE).

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Abciximab; Heparin; SR 123781; SR 123781
  • Indications Acute coronary syndromes; Embolism and thrombosis; Myocardial infarction; Unstable angina pectoris
  • Focus Therapeutic Use
  • Acronyms SHINE
  • Sponsors Sanofi
  • Most Recent Events

    • 11 Mar 2008 According to results presented at the ACC meeting, the primary outcome was met; however, treatment with the three lowest dosages of SR123781 was discontinued early due to a high incidence of catheter-related thrombosis.
    • 11 Mar 2008 Results were presented at the 57th Annual Scientific Session of the American College of Cardiology (ACC).
    • 02 Aug 2007 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top